Isomorphic Labs, Alphabet's AI-powered drug discovery company led by Nobel laureate Demis Hassabis, announced today that it has completed a $5 billion Series C funding round. The round was co-led by Greenoaks and Sequoia Capital, with new investors including a16z (Andreessen Horowitz) joining, continued significant investment from Alphabet, and participation from existing investors such as Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund. Isomorphic Labs plans to use the funds to continue advancing its foundational simulation models, scale internal and partnered drug candidate programs, and build global AI-driven bioengineering infrastructure.
Translation(model translation, not the source's own text)
Alphabet's drug AI company Isomorphic Labs completes $5 billion Series C funding
IT Home, November 17 news: Isomorphic Labs, an AI-enabled drug discovery company under Alphabet led by Nobel laureate Demis Hassabis, announced today local time that it has completed a Series C funding round totaling $5 billion (IT Home note: approximately 33.396 billion yuan at current exchange rates).
The round was co-led by Greenoaks and Sequoia Capital, with new investors including a16z (Andreessen Horowitz) joining, Alphabet continuing to invest heavily, and existing investors such as Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund also participating.
Isomorphic Labs plans to use the funds to continue advancing the development of foundational simulation models, scale up internal and partnered drug candidate programs, and build global AI-driven bioengineering infrastructure.
Related articles
Alphabet's AI drug discovery company Isomorphic Labs reportedly seeking funding at a $40–50 billion valuation
The translation is machine-generated and individual terms may be off. Nothing is rewritten or cut; the original is authoritative.
Published by IT之家
This site only summarises and aggregates; copyright stays with the original author. Headlines and summaries follow the source — where they differ, the original wins.